Table 2 Evaluation of the effectiveness of iron supplementation by comparing with control group
Author | Year | Journal | Study design | Inclusion criteria | N (iron) | N (control) | OP | Treatment timing | Additional treatment | PBM protocol | Iron | IV or Oral | Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Park et al. [26] | 2019 | J Clin Med | Randomized controlled trial | Hb ≥ 10 g/dLSerum-ferritin < 300 mg/dL (male) or 200 mg/dL (female) | 29 | 29 | TKA or THA | Intra-OP |  |  | FCM | IV | 1000 mg |
Heschl et al. [30] | 2018 | Eur J Anaesthesiol | Retrospective cohort study | Hb < 13 g/dL (men), <  12 g/dL (women) | 331 | 331 | TKA or THA | Pre-OP | +EPO |  | FCM | IV | 2*1 g |
Biboulet et al. [22] | 2018 | Anesthesiology | Randomized controlled trial | Hb: 10 ~ 13 g/dL | Oral 50 IV 50 |  | TKA or THA | Pre-OP | +EPO |  | IV: FCM Oral: Ferrous sulfate | Oral or IV | IV (1000 mg) Oral (160 mg*2/day for 3 weeks) |
Bisbe et al. [23] | 2014 | Br J Anaesth | Randomized controlled trial | Hb: 8.5 ~ 12.0 g/dL | Oral 62 IV 59 |  | TKA | Post-OP |  | Oral tranexamic acid, tourniquet | IV: FCM Oral: Ferrous sulfate | Oral or IV | IV: single IV injection by Ganzoni formula Oral: 100 mg/day for POD 7 ~ POD 30 |
Muñoz et al. [31] | 2014 | Blood transfusion | Retrospective cohort study | Hb ≥ 10 g/dL | 182 | 182 | TKA or THA | Post-OP |  | Tourniquet | Iron sucroseFCM | IV | 200 mg (3 consecutive post-operative days) or600 mg FCM on POD 1 |
Muñoz et al. [32] | 2012 | Br J Anaesth | Retrospective cohort study | Hb < 10 g/dL on POD 1 | Low dose 32High- dose 63 | 19 | TKA or THA | Post-OP |  |  | Iron sucroseFCM | IV | 100 mg* 3 days 200 mg* 3 days or 600 mg FCM |
Na et al. [25] | 2011 | Transfusion | Randomized controlled trial | Hb ≥ 10 g/dL andserum ferritin < 100 ng/L, orserum ferritin 100 ~ 300 ng/L and transferrin saturation < 20% | 54 | 54 | TKA (bilateral) | Intra-OP + Post-OP | +EPO |  | Iron sucrose | IV | 200 mg (Post-OP Hb 7 ~ 8 g/dL, injection 2 times more) |
Gonzalez-Porras et al. [29] | 2009 | Transfus Med | Prospective cohort study | Oral: Hb ≥ 13 g/dL and ferritin < 250 μg/LIV: Hb ≥ 13 g/dL and ferritin < 50 μg/L | 80 | 49 | TKA or THA | Pre-OP |  |  | Oral: ferrous sulfateIV: iron sucrose | Oral or IV | Oral: 315 mg/day IV: 200 mg/week (minimum 2 weeks) |
Mundy et al. [24] | 2005 | JBJS | Randomized controlled trial | Hb ≥ 13 g/dL (men), ≥ 11.5 g/dL (women)Serum-ferritin < 300 mg/dL (male) or 200 mg/dL (female) | 50 | 49 | TKA or THA | Post-OP |  |  | Ferrous sulfate | Oral | 200 mg three times daily (POD 2 ~ POD 3 weeks) |
Sutton et al. [27] | 2004 | JBJS | Randomized controlled trial | Hb ≥ 12 g/dL (men), ≥ 11 g/dL (women) | 35 | 37 | TKA or THA | Post-OP |  |  | Ferrous sulfate | Oral | 200 mg three times daily (~ 6 weeks after discharge) |
Weatherall et al. [28] | 2004 | ANZ J Surg | Randomized controlled trial | Hb ≥ 12 g/dL | 33 | 34 | TKA or THA | Post-OP |  |  | Ferrous gluconate | Oral | 325 mg (~ 10 weeks after surgery) |